Quality and Rate of Recovery after Simpliciti Anatomic Total Shoulder Arthroplasty and Tornier Pyrocarbon Hemiarthroplasty: A Propensity Score-Matched Comparative Study.
prospective_cohort · Level II
Where this comes from
- Record sourced from PubMed, PMID 42520884.
- Also identified by DOI 10.1016/j.jse.2026.07.011.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Simpliciti anatomic total shoulder arthroplasty (aTSA) and Tornier Pyrocarbon hemiarthroplasty (PyroC-HA) have been utilized with predictable benefit for the treatment of glenohumeral osteoarthritis (GHOA). The purpose of this study was to compare the rate of recovery and 2-year clinical outcomes in a matched group of patients undergoing these procedures. Prospectively collected preoperative, 3-, 6- and 24-month data were obtained from two Investigational Device Exemption studies evaluating the outcomes of patients who underwent stemless aTSA or PyroC-HA (n=157 each). A 1:1 propensity-score match was performed based on gender, age, BMI, diagnosis, glenoid morphology, baseline American Shoulder and Elbow Surgeon (ASES) and adjusted Constant scores. Seventy-four patients were identified for each cohort with no significant differences in covariates (all p>.103). Final outcome, change from baseline, and number of patients meeting the Minimal Clinically Important Difference (MCID) were evaluated for ASES score, total Constant, Constant strength, and pain score (0-10 scale). At baseline, each cohort (n=74) included 63 males (85%), and the primary diagnosis was GHOA in all patients. The average age of the aTSA cohort was 60.8 ± 7.3 years and 58.9 ± 6.6 years in the PyroC-HA cohort (p=0.103). Walch A1 was the most prevalent glenoid type in both cohorts (38% of aTSA patients and 45% of PyroC-HA). At 2 years there were 68 aTSA patients and 71 PyroC-HA patients included in the analysis. No significant differences in ASES scores were noted at any time point except for the 6 month score, which favored aTSA (83.5 points vs. 77.5, p=0.031). Average total Constant scores were not significantly different at any compared time point. There was a less than 1 point difference in pain between aTSA and PyroC-HA which was statistically significant at the 6-month and 24-month timepoints, with aTSA reporting an average pain level of 1.1 ± 1.5 compared to 1.8 ± 2.0 (p=0.018) at 6-months and 0.45 ± 0.95 vs. 1.06 ± 1.84 at 24-months (p=0.016). A statistically equivalent percentage of patients from each group achieved the MCID for ASES, Constant, and pain scores. Simpliciti aTSA and Tornier PyroC-HA are effective surgical treatments for younger patients with GHOA with similar outcomes at short-term follow-up. This study demonstrated that patients experienced similar recoveries and nearly identical two-year outcomes, with the exception of a statistically significant, less than 1 point difference in pain at 24 months postoperative.